Patent details
EP3417294 Title: METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB
Basic Information
- Publication number:
- EP3417294
- PCT Application Number:
- US2017017804
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP177537040
- PCT Publication Number:
- WO2017142871
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB
- French Title of Invention:
- PROCÉDÉS COMPRENANT UN DOSAGE INTERMITTENT ET FIXE DE CEDIRANIB
- German Title of Invention:
- VERFAHREN MIT FIXER INTERMITTIERENDER DOSIERUNG VON CEDIRANIB
- SPC Number:
Dates
- Filing date:
- 14/02/2017
- Grant date:
- 01/12/2021
- EP Publication Date:
- 26/12/2018
- PCT Publication Date:
- 24/08/2017
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 01/12/2021
- EP B1 Publication Date:
- 01/12/2021
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 14/02/2022
- Expiration date:
- 14/02/2037
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 01/04/2022
- Name:
- Astrazeneca AB
- Address:
- Forskargatan 18, 151 85 Södertälje, Sweden (SE)
- Name:
- The United States of America, as Represented By the Secretary, Department of Health and Human Services
- Address:
- National Institutes of Health Office of Technology Transfer 6701 Rockledge Drive Suite 700, MSC 7788, Bethesda, MD 20892, United States (US)
History of Owners
- From:
- 11/03/2022
- To:
- 01/04/2022
- Name:
- Astrazeneca AB
- Address:
- Forskargatan 18, 151 85 Södertälje, Sweden (SE)
- Name:
- The United States of America, as Represented By the Secretary, Department of Health and Human Services
- Address:
- Office of Technology Transfer 6701 Rockledge Drive Suite 700, MSC 7788, Bethesda, MD 20892, United States (US)
- From:
- 24/11/2021
- To:
- 11/03/2022
- Name:
- Astrazeneca AB
- Address:
- Forskargatan 18, 151 85 Södertälje, Sweden (SE)
- Name:
- The United States of America, as Represented By the Secretary, Department of Health and Human Services
- Address:
- Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard Suite 325 MSC 7660, Bethesda, MD 20892-7660, United States (US)
Inventor
1
- Name:
- WEDGE, Stephen, Robert
- Address:
- United Kingdom (GB)
2
- Name:
- LEE, Jung-Min
- Address:
- United States (US)
3
- Name:
- KOHN, Elise
- Address:
- United States (US)
4
- Name:
- IVY,Susan Percy
- Address:
- United States (US)
5
- Name:
- HO, Tony
- Address:
- United States (US)
6
- Name:
- BARRY, Simon
- Address:
- United Kingdom (GB)
7
- Name:
- KENDREW, Jane
- Address:
- United Kingdom (GB)
Priority
- Priority Number:
- 201662295421 P
- Priority Date:
- 15/02/2016
- Priority Country:
- United States (US)
Classification
- IPC classification:
- C07K 16/28; G01N 33/574; A61K 38/00; A61P 35/00; A61K 31/502; A61K 31/506; A61K 45/06; A61K 48/00; A61P 9/10; A61P 43/00; A61K 39/395;
Publication
European Patent Bulletin
1
- Issue number:
- 202148
- Publication date:
- 01/12/2021
- Description:
- Grant (B1)
2
- Issue number:
- 202201
- Publication date:
- 05/01/2022
- Description:
- Application number/publication number of the divisional application (Art. 76) changed
3
- Issue number:
- 202215
- Publication date:
- 13/04/2022
- Description:
- Change of owner's name or address
4
- Issue number:
- 202218
- Publication date:
- 04/05/2022
- Description:
- Change of owner's name or address
5
- Issue number:
- 202218
- Publication date:
- 04/05/2022
- Description:
- Document reprinted after correction (B8, B9)
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|